JMY Investments
Contributor since: 2013
Latest Articles
BioTime Approaches Inflection Point
Profits For Life
The Backdrop For PixarBio's Offer To Acquire InVivo Therapeutics
Intermap Technologies: A Case Study In Value Investing
Intermap Technologies: A Bear Turns Bullish
Perrigo Next Target For Activist Investor Starboard
If Xtera Can Solve Its Liquidity Crisis, It's A Home Run
Intermap Technologies: An Enterprise Value Approach
Here Comes Glass-Steagall: How It Will Impact Large Banks And Investors
The Trump Trade: Time To Buy Banks
Can Bluebird Bio Fly Again?
Starboard's Activist Campaign Puts Depomed In Play
Time To Buy Biotech Starting With AMAG Pharmaceuticals
Intermap Technologies: The Rest Of The Story
Treacherous Road Ahead For StemCells Investors
InVivo's Therapy On The Verge Of Becoming The De Facto Treatment For Spinal Cord Injury
You Don't Have To Be Smarter Than A 5th Grader To Know Cheniere Energy Is A Buy
A Closer Look At Johnson & Johnson's Collaboration With Geron
Inovio Pharmaceuticals And OncoSec Medical: Putting The Pieces Together
Chesapeake's Looming Liquidity Crisis
BioTime Could Be The Next Acquisition Target In The Stem Cell Sector
Intermap Technologies: A Top 10 List Of Investment Lessons
Intermap Technologies Corporation: Anatomy Of A Bad Investment
Nuvo Research: Two Companies For Less Than The Price Of One
A Case For Ocata Therapeutics
The Race To Treat Spinal Cord Injury: A Comparative Analysis
BioTime's Prospectus Setting Up Potential Divestiture Of Asterias Becomes Effective
Nuvo Research: Buy The Cash And Get The Company For Free
Dissecting StemCells Latest Capital Raise
InVivo Therapeutics: Time To Double Down
InVivo Therapeutics: Long Idea Playing Out With Room To Run
BioTime, Inc.: Following The Smart Money